Kernal Biologics, Inc. (Kernal Bio) — an early-development-stage mRNA-technology company developing cancer therapeutics designed to improve patients’ survival rate and quality of life — is on a fast track to transition out of proof-of-concept phase to product development. According to Co-founder and Chief Executive Officer Yusuf Erkul, M.D., the company has recruited a powerhouse team, which has enabled Kernal Bio to meet key scientific milestones. Kernal Bio’s mRNA technology combines two proprietary mRNA encryption designs, increasing the potential to improve patient outcomes resulting from an unprecedented level of onco-selectivity the company expects to achieve compared to existing synthetic mRNA technologies. Erkul believes it is their company’s culture of approaching problems in a multidisciplinary fashion that has made them successful to date. This includes building a machine learning-backed computational pipeline that engineers mRNAs to allow for evasion of innate immune sensors in the body and encrypts mRNAs to avoid activity in normal (non-cancerous) tissues.
For further information, see globenewswire ( Kernal Biologics Enters Development Phase Reaching Critical (globenewswire.com) )
